What's new

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 10, Status: Authorised

May 20, 2025 - 14:55
 0
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 10, Status: Authorised
Read More

Tags:

Previous Article

When the FDA requires a large vaccine trial, who pays?

Next Article

Israel buys $55 million in helo protection systems from Elbit for Apaches, Black...

Related Posts

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

May 15, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Gastroentology-Hepatology, PIP number: P/0038/2022

Opinion/decision on a Paediatric investigation plan (PI...

May 20, 2025  0

NovoSeven (eptacog alfa)

NovoSeven (eptacog alfa)

May 12, 2025  0